The PennZone

PHILADELPHIA, Nov. 21, 2023 /PRNewswire/ -- A securities fraud lawsuit has been filed against ACELYRIN, Inc. ("Acelyrin") (NASDAQ: SLRN). The lawsuit is captioned Aramouni v. Acelyrin, Inc., No. 2:23-cv-09672 (C.D. Cal.), and is filed on behalf of purchasers of Acelyrin's securities between May 4, 2023 and September 11, 2023, inclusive (the "Class Period").

CLICK HERE TO LEARN MORE ABOUT THIS LAWSUIT.

Investors who purchased or acquired Acelyrin securities during the Class Period may, no later than January 16, 2024, seek to be appointed as a lead plaintiff representative of the class.

The complaint alleges that, throughout the Class Period, the defendants made failed to disclose that: (i) izokibep was less effective in treating Hidradenitis Suppurativa than defendants had led investors to believe; (ii) accordingly, Acelyrin overstated izokibep's clinical and/or commercial prospects; and (iii) as a result, Acelyrin also overstated the company's business prospects post-IPO.

More on The PennZone

• Dr. Nadene Rose Shares the Secret to True Success: Faith, Obedience, and Divine Purpose
• Best Companies Group Opens Free Registration for Best Places to Work in Insurance Program
• Understanding Unexpected Death: Why Independent Autopsies Matter in Cases Without Clear Cause
• Epic Pictures Group Sets North American Release Date for the Thriller NO ORDINARY HEIST
• Mobile Copywriter Celebrates 13 Years of Content Creation and SEO Services

For additional information or to learn how to participate in this litigation, please contact Berger Montague: James Maro at [email protected] or (267) 637-3176, or Andrew Abramowitz at [email protected]  or (215) 875-3015 or CLICK HERE.

A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Communicating with any counsel is not necessary to participate or share in any recovery achieved in this case. Any member of the purported class may move the Court to serve as a lead plaintiff through counsel of his/her choice, or may choose to do nothing and remain an inactive class member.

More on The PennZone

• Award-Winning REALTOR® Paige Coker Joins Corcoran DeRonja Real Estate
• Over 98% of crypto owners globally don't declare taxes, new report find
• Happreneurs™ Business Community Launches Pittsburgh, PA Chapter with Powerful Network of Founding Leaders
• TicTac Group acquires French EdTech company Distrisoft
• Rhys-Davies, Wright, Norris, Jacinto Highlight Latest Wave of FAN EXPO Philadelphia Celebrity Guests

Berger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco and Chicago, has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.

Contacts:
James Maro, Senior Counsel
Berger Montague
(267) 637-3176
[email protected]

Andrew Abramowitz, Senior Counsel
Berger Montague
(215) 875-3015
[email protected]

SOURCE Berger Montague

---

Show All News | Report Violation